About us


iMAb uses its proprietary phage display technology to deliver to pharmaceutical and biotech customers the antibodies with the desired characteristics, fit for continued drug development.

 

Each project is assigned to a dedicated team, focused on a single target at a time, to configure project plans and antibody selection schemes adjusted to the antigen and objectives.

 

iMAb works in tandem with its corresponding academic platform "GenAc" and Inserm lab for very active research and R&D collaboration to continuously improve and innovate in our methods and tools.

Our Team


Our team gathers management excellence and top scientific expertise that can be traced back to the founding of fully human antibody phage display libraries.

Our MANAGEMENT TEAM

Bernard Pau PhD

Founder / Chief Executive Officer

 

Hon. Professor, Immunology, U-Montpellier.
Former Head of Dpt Life Sciences CNRS, Paris.

Top management, entrepreneur, expert in the development of Biotech & Pharma innovation.


Gautier Robin PhD

Founder / Chief Scientific Officer

 

PhD at University Joseph Fourier, Grenoble (Prof. R. H. Wade)
20 years of experience in academic and biotech research and management.

Expert in protein engineering and phage display.


Gordon Waldron

Founder

 

25 years experience working as CFO for start-ups primarily in the biotech sector.  
Raised > €150 million from international investor base and €50 million via IPO.
Negotiated the sale of Novexel for $500 million.


Pierre Martineau PhD

Founder

 

Engineer Polytechnique school.
PhD at Biotechnology Department, Institut Pasteur, Paris (Prof. M. Hofnung).
PostDoc at Cambridge (UK) Center for Protein Engineering (Sir G. Winter).
Team leader Inserm (IRCM, Montpellier).
Deputy Director, IRCM.


Bruno Robert PhD

Founder

 

PhD at University Montpellier (Dr. A. Pelegrin)
PostDoc at University of Lausanne (CH), Department of Biochemistry (Prof. J-P. Mach)
Inserm Scientist (IRCM, Montpellier)


Sylvain Yon PhD

Strategic and business development advisor

 

20 years of experience in medical devices and biotechnology startups. He is a co-founder of Echosens where he managed Technology and was chairman of the board until 2011. He is currently Deputy CEO of Theraclion, a public company developing solutions for non-invasive surgery. Sylvain is also an active business angel and strategic consultant for some very promising ventures in healthcare. He holds an engineering degree from ESPCI ParisTech and a PhD from Paris Diderot University.


Partners & collaborators